ALC Alcon Inc.

Alcon Prices US$750.0 Million Senior Notes Offering

Alcon (SIX/NYSE: ALC) announced that it has commenced and priced a private offering of US$750.0 million aggregate principal amount of its 2.600% senior notes due 2030 (the “Notes”). The Notes will be issued by Alcon Finance Corporation, Alcon’s indirect subsidiary, and will be fully and unconditionally guaranteed on a senior basis by Alcon.

The offering is expected to close on May 27, 2020, subject to customary closing conditions.

Alcon intends to use the proceeds from the offering for general corporate purposes.

Disclaimer

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Alcon’s current beliefs, expectations and assumptions regarding the future of Alcon’s business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in Alcon’s filings with the United States Securities and Exchange Commission, including Alcon’s Annual Report on Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Alcon assumes no obligation to update forward-looking statements as a result of new information, future events or otherwise.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities mentioned in this press release in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers of the Notes will be made only by means of a private offering memorandum to qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside of the United States under Regulation S under the Securities Act.

The Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.

EN
18/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alcon Inc.

 PRESS RELEASE

Alcon Publishes Agenda for 2024 Annual General Meeting

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to the AGM, including explanatory information on individual agenda items, will be publishe...

 PRESS RELEASE

Alcon Strengthens Leadership in IOL Innovation with the launch of the ...

BENGALURU, India--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India. Utilizing Alcon’s most advanced IOL material in its 20+ years of IOL innovation, Clareon delivers consistent visual outcomes and exceptional clarity that lasts.°,12-18 Clareon’s clarity is born out of a glistening-free§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs.†,*,12-14 The Clareon pla...

 PRESS RELEASE

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5¤ “Reaching the one million milestone for Vivity, the world's leading EDOF IOL, rep...

 PRESS RELEASE

Vivity, la LIO à profondeur focale accrue première au monde, atteint u...

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir brillamment, annonce aujourd’hui fièrement que les lentilles intraoculaires (LIO) à profondeur focale accrue AcrySofMD IQ VivityMD et ClareonMD Vivity ont dépassé plus d’un million d’implants dans le monde. Vivity est la LIO à profondeur focale accrue la plus implantée à l’échelle mondiale.1* Alcon est le chef de file mondial dans le domaine des LIO – toutes les quatre secondes une LIO Alcon est implantée – et continue d’innover dans ce domaine pour r...

 PRESS RELEASE

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5 “We are proud to celebrate the one million Vivity eyes empowering ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch